ASCO Approaches, Anticipation Mounts!

  • RSS Feed

- Roche’s T-DM1: Triple Threat To Breast Cancer or Another Avastin Disaster?

The upcoming American Society of Clinical Oncology (ASCO) meeting is one of the most highly anticipated events in the world of cancer pharmaceuticals. This year's 48th annual meeting will be held in Chicago from June 1-5, and investors and media outlets are already buzzing. The meeting abstracts released by ASCO on Wednesday, May 16 represent a "ho's who" of established and insurgent oncology companies. Exciting new data will be presented from biotechs like Medivation and Oncothyreon, who are gearing up for their first shot at regulatory approval, as well as from veteran players like Roche, Bayer and GlaxoSmithKline.

Gain full access to this article

You must register to read the full Expert Insight article. Register for FREE today and access all our healthcare Expert Insights.


Registering for our Expert Insights is free and only takes a moment.

Following this you'll gain unlimited access to all of the latest, event-driven opinion put together by our teams of experienced analysts.

Send to a colleague


© GlobalData 2015. John Carpenter House, 7 Carmelite Street, London EC4 0BS.